Copenhagen, Denmark and Buffalo Grove, Illinois, USA, 25 July, 2022 – We are pleased to share a study by Virginia Mason Institute (VMI), a consulting arm of Virginia Mason Franciscan Health who work with healthcare organizations globally. This study focusing on the impact of pre-mix intravenous medications in US hospital pharmacies, was sponsored by Xellia Pharmaceuticals USA LLC. Click on the link below to read a summary of the study, which highlights the impact that pre-mix medications can have on pharmacy team members including reduced stressors associated with compounding.